Based on the Axonics Modulation Technologies Inc stock forecast from 0 analysts, the average analyst target price for Axonics Modulation Technologies Inc is not available over the next 12 months. Axonics Modulation Technologies Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Axonics Modulation Technologies Inc is Slightly Bullish , which is based on 6 positive signals and 3 negative signals. At the last closing, Axonics Modulation Technologies Inc’s stock price was USD 70.98. Axonics Modulation Technologies Inc’s stock price has changed by +0.80% over the past week, +0.97% over the past month and +26.10% over the last year.
No recent analyst target price found for Axonics Modulation Technologies Inc
No recent average analyst rating found for Axonics Modulation Technologies Inc
Company Overview Axonics Modulation Technologies Inc
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California. As of November 15, 2024, Axonics, Inc. operates as a subsidiary of Boston Scientific Corporation. Address: 26 Technology Drive, Irvine, CA, United States, 92618 Read Less
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary...Read More
Frequently Asked Questions About Axonics Modulation Technologies Inc (AXNX) Stock
Stock Target Advisor's fundamental analysis for Axonics Modulation Technologies Inc's stock is Slightly Bullish .
Unfortunately we do not have enough data on AXNX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on AXNX's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on AXNX's stock to indicate if its overvalued.
The last closing price of AXNX's stock was USD 70.98.
The most recent market capitalization for AXNX is USD 3.63B.
Unfortunately we do not have enough analyst data on AXNX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Axonics Modulation Technologies Inc's stock.
As per our most recent records Axonics Modulation Technologies Inc has 797 Employees.
Axonics Modulation Technologies Inc's registered address is 26 Technology Drive, Irvine, CA, United States, 92618.
You can get more information about it from Axonics Modulation Technologies Inc's website at https://www.axonics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Axonics Modulation Technologies Inc (AXNX) Stock
Stock Target Advisor's fundamental analysis for Axonics Modulation Technologies Inc's stock is Slightly Bullish .
Unfortunately we do not have enough data on AXNX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on AXNX's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on AXNX's stock to indicate if its overvalued.
The last closing price of AXNX's stock was USD 70.98.
The most recent market capitalization for AXNX is USD 3.63B.
Unfortunately we do not have enough analyst data on AXNX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Axonics Modulation Technologies Inc's stock.
As per our most recent records Axonics Modulation Technologies Inc has 797 Employees.
Axonics Modulation Technologies Inc's registered address is 26 Technology Drive, Irvine, CA, United States, 92618.
You can get more information about it from Axonics Modulation Technologies Inc's website at https://www.axonics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AXNX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
